Brigit McLaughlin

Medicine · Health Sciences

9h-index1.8kcitations28works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(18), Cancer Genomics and Diagnostics(12), Radiopharmaceutical Chemistry and Applications(8), Cancer Cells and Metastasis(7), Lung Cancer Treatments and Mutations(3)

Publications28 total

Supplementary Methods & Figures S1-S5 from Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2023Open Access
Supplementary Methods & Figures S1-S5 from Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2023Open Access
Data from Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2023Open Access
Data from Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2023Open Access
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
JAMA Oncology·2018· 237 citedOpen Access
WS01.2 Phase 2 initial results evaluating PTI-428, a novel CFTR amplifier, in patients with cystic fibrosis
Journal of Cystic Fibrosis·2018· 9 citedOpen Access
Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2018· 8 cited
Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes
Annals of Oncology·2017Open Access
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
Cancer Research·2017· 134 citedOpen Access
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making
JCO Precision Oncology·2017· 519 cited
Abstract 1740: Phenotypic, genomic, and clinical associations of Circulating Tumor Cells (CTCs) lacking epithelial biomarkers in metastatic Castration Resistant Prostate Cancer (mCRPC)
Cancer Research·2017· 1 cited
Changes in CTC burden and prevalence of specific CTC subtypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapuetics (Tx).
Journal of Clinical Oncology·2017
Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A).
Journal of Clinical Oncology·2017
Single cell phenogenomic subtyping of circulating tumor cells (CTCs) identify intercellular tumor heterogeneity (het) and multiple resistance mechansisms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2017· 1 cited
Targeting reciprocal feedback inhibition: Apalutamide and everolimus in patients with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2017· 4 cited
Glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) to prognosticate overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with androgen receptor signaling inhibitors (ARSi).
Journal of Clinical Oncology·2017· 2 cited
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
European Urology·2016· 181 citedOpen Access
Impact of AR-V7 protein localization in the prediction of therapeutic benefit of taxanes over androgen receptor signaling inhibitors (ARSi) in metastatic castration resistant prostate cancer (mCRPC)
Annals of Oncology·2016
Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size
Journal of Virology·2016· 21 citedOpen Access
Abstract 4954: Nuclear localized AR-V7 protein as a predictive biomarker for treatment selection in metastatic castration resistant prostate cancer (mCRPC)
Cancer Research·2016
page 1 of 2Next →

Frequent Co-authors

Howard I. Scher(23), Nicole A. Schreiber(21), Ryon P. Graf(21), Ryan Dittamore(21), Martin Fleisher(18), Adam Jendrisak(16), Yipeng Wang(14), Mark Landers(13), Glenn Heller(12), Jerry Lee(12), Lyndsey Dugan(10), David Lu(9), Jessica Louw(8), Stephanie Greene(8), Hebert Alberto Vargas(7), Ángel Rodríguez(7), Ann Johnson(5), Daniel C. Danila(5), Rachel Krupa(5), Pascal Bamford(5)